Figure 5
T1% period in immunized mice after challenge with Pb-PvCSP transgenic sporozoites. Groups of six C57BL/6 mice were s.c. immunized with the vaccine formulations in the presence of Poly (I:C) or Montanide adjuvants, following the scheme shown in Table 1. Upper panel: Immunized mice were challenged 14 days after the third dose with 2,000 Pb-PvCSPVK210 sporozoites. Percent protection to reach 1% parasitemia (a, b) and follow-up analysis of parasitemia at days 4, 5 and 6 after challenge (c, d) is shown. Middle panel: Immunized mice were challenged 14 days after the third dose with 2,000 Pb-PvCSPVK247 sporozoites. Percent protection to reach 1% parasitemia (e, f) and follow-up analysis of parasitemia at days 4, 5 and 6 after challenge (g, h) is shown. Lower panel: Immunized mice were challenged 14 days after the third dose with 2000 spz of the new chimeric Pb-PvCSP-like G10 parasite. Percent protection to reach 1% parasitemia (i, j) and follow-up analysis of parasitemia at days 4, 5 and 6 after challenge (k, l) is shown. Significant differences in T1% periods (see Table 2) were analyzed by applying the log-rank (Mantel-Cox) test.
